Peter Houghton, PhD

Peter J. Houghton, PhD, is director of the Center for Childhood Cancer at The Research Institute. With his guidance, Nationwide Children’s is poised to develop new, clinically-applicable cancer therapies and expand and enhance its clinical trial programs. Dr. Houghton also has an integral role with The Ohio State University Comprehensive Cancer Center and holds a faculty post at The Ohio State University College of Medicine. Dr. Houghton came to Columbus after a more than 30-year stint with St. Jude Children’s Research Hospital in Memphis, Tenn., where he was the chairman of Molecular Pharmacy, director of the Solid Tumor Program Project Grant, and co-leader of the Solid Malignancies Program. During his career, Dr. Houghton has focused on understanding the basic biology of childhood solid tumors, largely sarcomas. His track record of groundbreaking laboratory discovery distinguishes him as a national leader in pediatric cancer research. Dr. Houghton’s expertise covers many areas of study, though he is most noted for the discovery of new therapies to treat tumors occurring in muscles and other soft tissues, especially rhabdomyosarcomas. This type of tumor is one of the most common and highly malignant cancers occurring in children. Along with his lab-based studies, Dr. Houghton brought the Pediatric Preclinical Testing Program (PPTP) to Nationwide Children’s. The PPTP provides a system for prioritizing drugs with potential to treat pediatric cancers. Supported by the National Cancer Institute, the PPTP involves multiple pediatric research sites throughout the world that have expertise in specific childhood cancers. Scientists at these sites have developed preclinical models that express genes similar to those expressed by human cancers. These models are used to determine which drugs that have been developed for adult cancers may be effective in treating pediatric cancers. The PPTP not only helps prioritize drugs for pediatrics, but helps fast track these therapies to trials in children. Dr. Houghton received his PhD in 1976 from the Institute of Cancer Research at the University of London.

Gender:

• Male

Languages Spoken:

• English

Research Center:

• Center for Childhood Cancer

Areas of Interest:

• Pediatric Preclinical Testing Program The Pediatric Preclinical Testing Program (PPTP) is a comprehensive program to systematically evaluate new agents against childhood solid tumor and leukemia models. The PPTP is supported through an NCI research contract to The Research Institute at Nationwide Children's Hospital with Dr. Peter Houghton as the Principal Investigator. Testing occurs both at The Research Institute and also at subcontract sites that have expertise in specific childhood cancers. The program is based on a substantial body of data showing that appropriate childhood cancer preclinical in vivo models can recapitulate the anti-tumor activity of known effective agents and can prospectively identify novel agents subsequently shown to have clinical activity against specific cancers of children and adolescents. By facilitating development of a more reliable pediatric new agent prioritization process, the PPTP will contribute to the goal of identifying more effective treatments for children with cancer.
• Antibodies as Potential IGF Inhibitors Antibodies are being considered a potential therapy to block IGF signaling. Studies have shown that antibodies cannot equally block both IGF1 and IGF2 ligands since they are overlapping sites on the receptor, but are not identical. Dr. Houghton has found that there are very marked differences between antibodies that block IGF1 versus those that block IGF2. The IGF1 blockers seem to perform better against Ewing sarcoma and osteosarcoma; the IGF2 blockers seem to perform better against rhabdomyosarcoma and other tumors. Dr. Houghton’s Lab is working to tease out these subtitles, which could be critical as to whether or not a child responds to treatment.
• The Houghton Lab is focused on understanding the basic biology of childhood solid tumors, largely sarcoma. Dr. Houghton has identified a chromosomal rearrangement in rhabdomyosarcoma that leads to downstream over-expression of insulin-like growth factor 2 (IGF2) ligand. His lab is working to interpret the signaling pathway and is developing therapeutic approaches to block IGF signaling in rhabdomyosarcoma, Wilms’ tumors, neuroblastoma, Ewing sarcomas, and a range of other tumors.
• Combining Rapamycin with IGF Inhibitors When rapamycin is used to block the kinase TOR in the absence of insulin-like growth factors, cellular response is death and not quiescence. However, this only occurs when tumor suppressor p53 is attenuated, which is common in most pediatric cancers. Multiple clinical trials are ongoing or planned to examine the effect that combining rapamycin with an IGF inhibitor has on childhood cancer.
• Using Rapamycin to Block TOR In 1992 Dr. Houghton’s Lab identified rapamycin as a drug that potently blocked IGF-driven proliferation of sarcoma cells. This agent blocks a very specific kinase (TOR) that is downstream of the IGF1 receptor. The kinase targeted by rapamycin regulates autophagy, cell cycle progression, survival and transcription. The team is working to understand which of these processes are critical for tumor cell survival under stress, and to define how low oxygen (hypoxia) regulates the activity of mTOR. Use of rapamycin for treatment of childhood cancer is currently in Phase II clinical trials.

Undergraduate

• University of Bradford - B.Ph
  Date Completed: 06/30/1972

Graduate School

• Royal Pharmaceutical Society of Great Britain -MPS
  Date Completed: 06/30/1973

Post Doctoral

• University of London, Division of Biophysics, Institute of Cancer Research
  Date Completed: 06/30/1976

2009–present

• Elizabeth M. & Richard M. Ross Endowed Chair in Pediatric Research 

2009–present

• Director, Center for Childhood Cancer, The Research Institute at Nationwide Children's Hospital, Columbus, OH

2004–present

• Principle Investigator for the Pediatric Preclinical Testing Program contract
  

2003–present

• Member, Biology Committee, Children’s Oncology Group

2002–present

• Member Steering Committee, Phase I Consortium, Children’s Oncology Group.

2000–present

• Member Developmental Therapeutics Committee, Children's Oncology Group.Chair, Biology sub-committee.

2003–2006

• Chair, Drug Discovery and Molecular Pharmacology Study Section, NIH.

1992–2009

• Chairman, Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee

• Kolb EA; Gorlick R; Lock R; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups C; Smith MA; Houghton PJ. 2011. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.  Pediatric Blood & Cancer. Vol. 56, no. 4. (April 1): 595.
• Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ. 2011. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.  Pediatr Blood Cancer.. Vol. 4, no. 56. (April): 595-603.
• Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, Gorlick R, Kolb EA, Keir ST, Wu J, Wozniak AE, Yang Y, Manfredi M, Ecsedy J, Wang J, Neale G, Houghton PJ, Smith MA, Lock RB. 2011. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.  Cancer Chemother Pharmacol. (March 30) . PubMed ID: 21448591
• Smith MA, Maris JM, Lock R, Kolb EA, Gorlick R, Keir ST, Carol H, Morton CL, Reynolds CP, Kang MH, Houghton PJ. 2011. Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.  Pediatr Blood Cancer. Vol. 10. (February 25): 1002.
• Reynolds CP, Kang MH, Keir ST, Gorlick R, Kolb EA, Lock R, Maris JM, Carol H, Morton CL, Billups CA, Smith MA, Houghton PJ. 2011. Initial testing of lenalidomide by the pediatric preclinical testing program.  Pediatr Blood Cancer. Vol. 10. (February 25): 1002.
• Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Phelps D, Maris JM, Billups C, Smith MA. 2011. Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program.  Pediatr Blood Cancer.. Vol. 10. (February 18): 1002.
• Kang MH; Smith MA; Morton CL; Keshelava N; Houghton PJ; Reynolds CP. 2011. National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.  Pediatric Blood & Cancer. Vol. 56, no. 2. (February 1): 239.
• Bid HK; Houghton PJ. 2011. Targeting angiogenesis in childhood sarcomas.  Sarcoma. Vol. 2011. (January 1): 601514.
• Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gu Y, Wilson WR, Smith MA. 2010. Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.  Pediatr Blood Cancer.. (December 27)
• Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ. 2010. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.  . Pediatr Blood Cancer. (December 22)
• Carol H; Morton CL; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups C; Smith MA; Houghton PJ; Lock RB. 2010. Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.  Pediatric Blood & Cancer. Vol. 55, no. 7. (December 15): 1329.
• Keir ST; Maris JM; Lock R; Kolb EA; Gorlick R; Carol H; Morton CL; Reynolds CP; Kang MH; Watkins A; Houghton PJ; Smith MA. 2010. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program.  Pediatric Blood & Cancer. Vol. 55, no. 6. (December 1): 1126.
• Houghton PJ; Morton CL; Kang M; Reynolds CP; Billups CA; Favours E; Payne-Turner D; Tucker C; Smith MA. 2010. Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program.  Pediatric Blood & Cancer. Vol. 55, no. 6. (December 1): 1224.
• Cam H, Easton JB, High A, Houghton PJ. 2010. mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1?.  Mol Cell. Vol. 4, no. 40. (November 24): 509-520.
• Cam H; Easton JB; High A; Houghton PJ. 2010. mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1?.  Molecular Cell. Vol. 40, no. 4. (November 24): 509.
• Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA. 2010. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.  Pediatr Blood Cancer. Vol. 4, no. 55. (October): 668-677.
• Kolb EA; Gorlick R; Houghton PJ; Morton CL; Neale G; Keir ST; Carol H; Lock R; Phelps D; Kang MH; Reynolds CP; Maris JM; Billups C; Smith MA. 2010. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.  Pediatric Blood & Cancer. Vol. 55, no. 4. (October 1): 668.
• Morton CL; Houghton PJ; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Maris JM; Keir ST; Wu J; Smith MA. 2010. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program.  Pediatric Blood & Cancer. Vol. 55, no. 2. (August 1): 295.
• Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ. 2010. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).  Pediatric Blood & Cancer. Vol. 55, no. 1. (July 15): 26.
• Kolb EA; Kamara D; Zhang W; Lin J; Hingorani P; Baker L; Houghton P; Gorlick R. 2010. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.  Pediatric Blood & Cancer. Vol. 55, no. 1. (July 15): 67.
• Houghton PJ; Morton CL; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Wu J; Smith MA. 2010. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.  Pediatric Blood & Cancer. Vol. 54, no. 7. (July 1): 921.
• Carol H; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Maris JM; Keir ST; Watkins A; Smith MA; Lock RB. 2010. Initial testing of topotecan by the pediatric preclinical testing program.  Pediatric Blood & Cancer. Vol. 54, no. 5. (May 1): 707.
• Ritchie MF; Yue C; Zhou Y; Houghton PJ; Soboloff J. 2010. Wilms tumor suppressor 1 (WT1) and early growth response 1 (EGR1) are regulators of STIM1 expression.  The Journal Of Biological Chemistry. Vol. 285, no. 14. (April 2): 10591.
• Thimmaiah KN; Easton JB; Houghton PJ. 2010. Protection from rapamycin-induced apoptosis by insulin-like growth factor-I is partially dependent on protein kinase C signaling.  Cancer Research. Vol. 70, no. 5. (March 1): 2000.
• Houghton PJ. 2010. Everolimus.  Clinical Cancer Research: An Official Journal Of The American Association For Cancer Research. Vol. 16, no. 5. (March 1): 1368.
• Smith MA; Morton CL; Kolb EA; Gorlick R; Keir ST; Carol H; Lock R; Kang MH; Reynolds CP; Maris JM; Watkins AE; Houghton PJ. 2010. Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program.  Pediatric Blood & Cancer. Vol. 54, no. 2. (February 1): 307.
• Polunovsky, Vitaly A., Houghton, Peter J., ed. 2010. Targeting mTOR Effectors: Attacking the Translational Apparatus as a Nexus of Oncogenic Circuitry. New York, New York, United States: Humana Press. www.springer.com.
• Kurmasheva, Raushan T., Hosoi, Hajime, Kikuchi, Ken, Houghton, Peter J. 2010. Molecular Therapy for Rhabdomyosarcoma. In Molecularly Targeted Therapy for Childhood Cancer. Edited by Houghton, Peter J., Arceci, Robert J. New York, New York, United States: Springer. 425-458. www.springer.com.
• Houghton, P. J., C. L. Morton, et al. "Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program." Pediatr Blood Cancer. PubMed ID: 20166202
• Houghton, Peter J; Arceci, Robert J., ed. 2010. Molecularly Targeted Therapy for Childhood Cancer. New York, New York, United States: Springer. www.springer.com.
• Maris, J. M., C. L. Morton, et al. "Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)." Pediatr Blood Cancer. PubMed ID: 20108338
• Houghton, Peter J. 2010. mTor and Cancer Therapy: General Principles. In mTOR Pathway and mTOR Inhibitors in Cancer Therapy. Edited by Polunovsky, Vitaly A., Houghton, Peter J. New York, New York, United States: Humana Press. 113-131. www.springer.com.
• Wu J; Houghton PJ. 2010. Interval approach to assessing antitumor activity for tumor xenograft studies.  Pharmaceutical Statistics. Vol. 9, no. 1. (January 1): 46.
• Houghton, Peter J. 2010. mTOR and Cancer Therapy: General Principles. In mTOR as a Target for Cancer Therapy. Edited by Polunovsky, Vitaly A., Houghton, Peter J. New York, New York, United States: Humana Press. 113-131. www.springer.com.
• Houghton PJ; Morton CL; Gorlick R; Lock RB; Carol H; Reynolds CP; Kang MH; Maris JM; Keir ST; Kolb EA; Wu J; Wozniak AW; Billups CA; Rubinstein L; Smith MA. 2010. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program.  Molecular Cancer Therapeutics. Vol. 9, no. 1. (January 1): 101.
• Smith MA, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Kang MH, Reynolds CP, Maris JM, Watkins AE, Houghton PJ.Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010 Feb;54(2):307-10. PubMed ID: 19856388
• Polunovsky, Vitaly A.; Houghton, Peter J., ed. 2010. nTOR Pathway and mTOR Inhibitors in Cancer Therapy. New York, New York, United States: Humana Press. www.springer.com.
• Houghton, P. J., C. L. Morton, et al. "Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program." Mol Cancer Ther 9(1): 101-12. PubMed ID: 20053767
• Houghton, P. J. "Everolimus." Clin Cancer Res 16(5): 1368-72.
• Polunovsky, Vitaly A., Houghton, Peter J., ed. 2010. mTOR as a Target for Cancer Therapy. New York, New York, United States: Humana Press. www.springer.com.
• Carol H; Lock R; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA. 2009. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.  Pediatric Blood & Cancer. Vol. 53, no. 7. (December 15): 1255.
• Carol H, Lock R, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009 Dec 15;53(7):1255-63. PubMed ID: 19554570
• Keshelava N, Houghton PJ, Morton CL, Lock RB, Carol H, Keir ST, Maris JM, Reynolds CP, Gorlick R, Kolb EA, Wu J, Smith MA.Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009 Sep;53(3):505-8. PubMed ID: 19418547
• Wu, J. and P. J. Houghton (2009). "Assessing cytotoxic treatment effects in preclinical tumor xenograft models." J Biopharm Stat 19(5): 755-62. PubMed ID: 20183441
• Carol, H., P. J. Houghton, et al. "Initial testing of topotecan by the pediatric preclinical testing program." Pediatr Blood Cancer 54(5): 707-15. PubMed ID: 20017204
• Gorlick, R., E. A. Kolb, et al. (2009). "Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program." Pediatr Blood Cancer 53(4): 594-8. PubMed ID: 19554571
• Kurmasheva, R. T., L. Dudkin, et al. (2009). "The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma." Cancer Res 69(19): 7662-71. PubMed ID: 19789339
• Wu, J. and P. J. Houghton "Interval approach to assessing antitumor activity for tumor xenograft studies." Pharm Stat 9(1): 46-54. PubMed ID: 19306260
• Shu, L. and P. J. Houghton (2009). "The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts." Mol Cell Biol 29(17): 4691-700. PubMed ID: 19564418
• Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA.Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.
  Pediatr Blood Cancer. 2008 Jul;51(1):42-8. PubMed ID: 18293383
• Keir ST, Morton CL, Billups C, Smith MA, Houghton PJ, Gururangan S.Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Sep;51(3):439-41. PubMed ID: 18493996
• Houghton, P. J., C. L. Morton, et al. (2008). "Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program." Pediatr Blood Cancer 50(1): 37-45. PubMed ID: 17420992
• Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA.Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jun;50(6):1190-7. PubMed ID: 18260118
• Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Wu J, Smith MA.Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program.
  Pediatr Blood Cancer. 2008 Jun;50(6):1181-9. PubMed ID: 18085673
• Tajbakhsh M, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Maris JM, Keir ST, Wu J, Reynolds CP, Smith MA, Lock RB. Initial testing of cisplatin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 May;50(5):992-1000.
  PubMed ID: 17554786
• Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock RB, Tajbakhsh M, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jun;50(6):1198-206. PubMed ID: 17914733
• Smith MA, Morton CL, Phelps D, Girtman K, Neale G, Houghton PJ. SK-NEP-1 and Rh1 are Ewing family tumor lines. Pediatr Blood Cancer. 2008 Mar;50(3):703-6. PubMed ID: 17154184
• Houghton, P. J., C. L. Morton, et al. (2008). "Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program." Pediatr Blood Cancer 50(4): 799-805. PubMed ID: 17635004
• Houghton, P. J., C. L. Morton, et al. "Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program." Pediatr Blood Cancer. PubMed ID: 20166202
• Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J, Khoury J, Triche TJ, Seeger RC, Gilbertson R, Khan J, Smith MA, Houghton PJ.Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res. 2008 Jul 15;14(14):4572-83. PubMed ID: 18628472
• Smith MA, Morton CL, Phelps DA, Kolb EA, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Wu J, Houghton PJ.Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.
  Pediatr Blood Cancer. 2008 Jul;51(1):34-41. PubMed ID: 18260120
• Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA.Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Mar;50(3):581-7. PubMed ID: 17457854
• Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA.The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2007 Dec;49(7):928-40. PubMed ID: 17066459
• Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, Smith MA.Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res. 2002 Dec;8(12):3646-57. PubMed ID: 12473573